Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

SCOPE

Financiado

Leveraging CRISPR-Cas for fast and accurate point-of-care diagnostics

In the healthcare sector, rapid and precise point-of-care diagnostics is indispensable for enhancing patient outcomes, particularly in critical scenarios such as sepsis and organ transplantations. Present In Vitro Diagnostic techn... ver más

28/02/2026

SCOPE BIOSCIENCES...

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

SCOPE BIOSCIENCES B.V. No se ha especificado una descripción o un objeto social para esta compañía.

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2024-02-21

HORIZON-EIC-2023-TRANSITIONCHALLENGES-01: EIC Transition Challenge: Full scal... Scope:The scope of the Challenge is the maturation of Micro-Nano-Bio technologies developed in previ...

I+D

Cerrada hace 1 año

0% 100% 100%

1 Participantes

SCOPE BIOSCIENCES B.V.

2.50M€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

FIEC13-3E-2657 DOTACIÓN A LA UNIDAD DE APOYO A LA INVESTIGACIÓN DEL HCUV DE... 110K€ Cerrado

RTC2019-007023-1 Desarrollo de kits diagnósticos mediante PCR multiplex en ti... 747K€ Cerrado

AMPD At-home, Maximised Potential DNA/RNA Detecting Device 173K€ Cerrado

UNAM15-CE-3724 Sistema de amplificación y cuantificación de ácidos nucleico... 115K€ Cerrado

PRONTO self-PoweRed cONductimeter for digiTalization of rapid mOlec... 150K€ Cerrado

PDC2022-133941-I00 DESARROLLO DE UNA PLATAFORMA DE DIAGNOSTICO RAPIDO BASADA EN... 138K€ Cerrado

Duración del proyecto: 24 meses Fecha Inicio: 2024-02-21
Fecha Fin: 2026-02-28

Líder del proyecto

SCOPE BIOSCIENCES B.V. No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 2M€

Descripción del proyecto In the healthcare sector, rapid and precise point-of-care diagnostics is indispensable for enhancing patient outcomes, particularly in critical scenarios such as sepsis and organ transplantations. Present In Vitro Diagnostic technologies often strike a compromise between accuracy, speed, portability, and cost-effectiveness. Immunoassays offer rapidity but sacrifice accuracy, while molecular diagnostics like PCR deliver accuracy at the expense of time and ease of use. Isothermal molecular tests, on the other hand, are swift but lack specificity. Hence, a pressing need persists for point-of-care diagnostic tools that embody user-friendliness, cost-efficiency, high accuracy, and adaptability to diverse applications. At Scope Biosciences, a spin-off from Wageningen University, we have developed and patented a CRISPR-Cas diagnostic technology (scopeDx) that harnesses the precision of PCR and the speed of isothermal amplification, delivering rapid results within approximately 30 minutes at the point of care. Futhermore, the scopeDx platform can be rapidly adapted to new applications. Our objective is to complete the pre-clinical validation of our solution to offer user-friendliness, robustness, portability, and cost-effectiveness, providing swift results directly at the point-of-care. Besides, we aim to prove the versatility of our platform, which can be extended to the detection of various pathogenic microbes (viruses, bacteria, fungi) and genomic applications (stem-cell & tissue transplantations). In essence, scopeDx constitutes a modular platform technology with the potential to revolutionize the point-of-care diagnostics market comprehensively.

Conecta tu I+D

Entra hoy

¿Olvide mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores